Literature DB >> 21091666

Therapeutic failure in American cutaneous leishmaniasis is associated with gelatinase activity and cytokine expression.

A C Maretti-Mira1, M P de Oliveira-Neto, A M Da-Cruz, M P de Oliveira, N Craft, C Pirmez.   

Abstract

Cutaneous lesions caused by Leishmania braziliensis infection occasionally heal spontaneously, but with antimonials therapy heal rapidly in approximately 3 weeks. However, about 15% of the cases require several courses of therapy. Matrix metalloproteinase-2 (MMP-2) and MMP-9 are gelatinases that have been implicated in other chronic cutaneous diseases and skin re-epithelialization. These enzymes are controlled by their natural inhibitors [tissue inhibitors of metalloproteinase (TIMPs)] and by some cytokines. Uncontrolled gelatinase activity may result in intense tissue degradation and, consequently, poorly healing wounds. The present study correlates gelatinase activity to therapeutic failure of cutaneous leishmaniasis (CL) lesions. Our results demonstrate an association between gelatinase activity and increased numbers of cells making interferon (IFN)-γ, interleukin (IL)-10 and transforming growth factor (TGF)-β in lesions from poor responders. Conversely, high levels of MMP-2 mRNA and enhanced MMP-2 : TIMP-2 ratios were associated with a satisfactory response to antimonials treatment. Additionally, high gelatinolytic activity was found in the wound beds, necrotic areas in the dermis and within some granulomatous infiltrates. These results indicate the importance of gelatinase activity in the skin lesions caused by CL. Thus, we hypothesize that the immune response profile may be responsible for the gelatinase activity pattern and may ultimately influence the persistence or cure of CL lesions.
© 2010 The Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21091666      PMCID: PMC3043311          DOI: 10.1111/j.1365-2249.2010.04285.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  42 in total

1.  Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro.

Authors:  M D Sadick; R M Locksley; C Tubbs; H V Raff
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

2.  Modulation of monocytes matrix metalloproteinase-2, MT1-MMP and TIMP-2 by interferon-gamma and -beta: implications to multiple sclerosis.

Authors:  Yanina Galboiz; Sarah Shapiro; Nitza Lahat; Ariel Miller
Journal:  J Neuroimmunol       Date:  2002-10       Impact factor: 3.478

3.  Ectopic localization of matrix metalloproteinase-9 in chronic cutaneous wounds.

Authors:  Ursula Mirastschijski; Ulla Impola; Tiina Jahkola; Tonny Karlsmark; Magnus S AGren; Ulpu Saarialho-Kere
Journal:  Hum Pathol       Date:  2002-03       Impact factor: 3.466

4.  Mechanisms associated with immunoregulation in human American cutaneous leishmaniasis.

Authors:  M Castés; A Agnelli; A J Rondón
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

5.  Cutaneous leishmaniasis: immune complex formation and necrosis in the acute phase.

Authors:  M J Ridley; D S Ridley
Journal:  Br J Exp Pathol       Date:  1984-06

6.  Matrix metalloproteinase inhibitor GM 6001 attenuates keratinocyte migration, contraction and myofibroblast formation in skin wounds.

Authors:  Ursula Mirastschijski; Carol J Haaksma; James J Tomasek; Magnus S Agren
Journal:  Exp Cell Res       Date:  2004-10-01       Impact factor: 3.905

7.  The essential involvement of cross-talk between IFN-gamma and TGF-beta in the skin wound-healing process.

Authors:  Yuko Ishida; Toshikazu Kondo; Tatsunori Takayasu; Yoichiro Iwakura; Naofumi Mukaida
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

8.  Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients.

Authors:  R Lobmann; A Ambrosch; G Schultz; K Waldmann; S Schiweck; H Lehnert
Journal:  Diabetologia       Date:  2002-05-25       Impact factor: 10.122

9.  Interleukin 10 blocks matrix metalloproteinase-2 and membrane type 1-matrix metalloproteinase synthesis in primary human prostate tumor lines.

Authors:  Mark E Stearns; Min Wang; Youji Hu; Fernando U Garcia; Johng Rhim
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531

10.  The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure.

Authors:  Y Belkaid; K F Hoffmann; S Mendez; S Kamhawi; M C Udey; T A Wynn; D L Sacks
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

View more
  8 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

Review 2.  The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis.

Authors:  Mary-Anne Hartley; Stefan Drexler; Catherine Ronet; Stephen M Beverley; Nicolas Fasel
Journal:  Trends Parasitol       Date:  2014-06-20

3.  Early Cutaneous Leishmaniasis Patients Infected With Leishmania braziliensis Express Increased Inflammatory Responses After Antimony Therapy.

Authors:  Rúbia S Costa; Lucas P Carvalho; Taís M Campos; Andréa S Magalhães; Sara T Passos; Albert Schriefer; Juliana A Silva; Ednaldo Lago; Camilla S Paixão; Paulo Machado; Phillip Scott; Edgar M Carvalho
Journal:  J Infect Dis       Date:  2018-02-14       Impact factor: 5.226

4.  Proteinases as virulence factors in Leishmania spp. infection in mammals.

Authors:  Mariana Silva-Almeida; Bernardo Acácio Santini Pereira; Michelle Lopes Ribeiro-Guimarães; Carlos Roberto Alves
Journal:  Parasit Vectors       Date:  2012-08-07       Impact factor: 3.876

5.  Infection with Leishmania major induces a cellular stress response in macrophages.

Authors:  Alessandra A Filardy; Ana Caroline Costa-da-Silva; Carolina M Koeller; Kamila Guimarães-Pinto; Flávia L Ribeiro-Gomes; Marcela F Lopes; Norton Heise; Célio G Freire-de-Lima; Marise P Nunes; George A DosReis
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

6.  Matrix metalloproteinase 9 production by monocytes is enhanced by TNF and participates in the pathology of human cutaneous Leishmaniasis.

Authors:  Taís M Campos; Sara T Passos; Fernanda O Novais; Daniel P Beiting; Rúbia S Costa; Adriano Queiroz; David Mosser; Phillip Scott; Edgar M Carvalho; Lucas P Carvalho
Journal:  PLoS Negl Trop Dis       Date:  2014-11-13

Review 7.  Cytotoxic activity in cutaneous leishmaniasis.

Authors:  Taís M Campos; Rúbia Costa; Sara Passos; Lucas P Carvalho
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-11       Impact factor: 2.743

8.  Dual Role of Insulin-Like Growth Factor (IGF)-I in American Tegumentary Leishmaniasis.

Authors:  Carolina de O Mendes-Aguiar; Camilla Lopes-Siqueira; Fabrício Pettito-Assis; Márcia Pereira-Oliveira; Manoel Paes de Oliveira-Neto; Claude Pirmez; Alda Maria Da-Cruz; Hiro Goto
Journal:  J Immunol Res       Date:  2021-03-29       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.